This is a randomized Phase IIa, multi-center, double-blind, placebo-controlled study of a new buccal film of montelukast in patients with mild to moderate Alzheimer's Disease.
50 years or older, with mild to moderate Alzheimer’s Disease
Participants will receive drug treatment via IV in clinic on Day 1 and every 4 weeks thereafter.
Multi-center, Double-Blind, Placebo-Controlled Phase 1/2 Trial to Assess the Safety and Tolerability of WVE-3972-01 Administered Intrathecally to Patients with Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD).
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period.
A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE).
A Phase 3 randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
This is a phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study that will assess efficacy and safety of AL002 administered intravenously (IV) in participants with Early Alzheimer's Disease.
The primary objective of this study is to investigate the safety and efficacy of simufilam (PTI-125) in enhancing cognition and slowing cognitive and functional decline following 76-week, repeat-dose oral administration in participants with mild-to-moderate AD.